Table 1.
Demographic and clinical characteristics of patients.
| Number of Patients (%) | ||
|---|---|---|
| Gender | Female | 94 (50.8) |
| Male | 91 (49.2) | |
| Stage at Diagnosis | IA | 76 (41.0) |
| IB | 73 (39.5) | |
| IIA | 36 (19.5) | |
| T Stage at Diagnosis | T1 | 88 (47.6) |
| T2 | 97 (52.4) | |
| N Stage at Diagnosis | N0 | 82 (44.3) |
| Nx | 67 (36.2) | |
| N1 | 36 (19.5) | |
| B Stage at Diagnosis | B0 | 180 (97.3) |
| B1 | 5 (2.7) | |
| Patch/Plaque | Patch | 79 (42.7) |
| Patch + Plaque | 106 (57.3) | |
| Morphological Findings | Erythematous | 120 (64.8) |
| Hyperpigmented | 35 (18.9) | |
| Poikiloderma | 13 (7.0) | |
| Folliculotropism | 9 (4.8) | |
| PPD-like | 7 (3.8) | |
| Hypopigmented | 3 (1.6) | |
| GSS | 1 (0.5) | |
| Ichthyosiform | 1 (0.5) | |
| Pruritus | No | 77 (41.6) |
| Yes | 108 (58.4) | |
| LDH Levels | Normal | 170 (91.9) |
| High | 15 (8.1) | |
| β-2 Microglobulin Levels | Normal | 121 (65.4) |
| High | 64 (34.6) | |
| Eosinophilia | No | 174 (94.0) |
| Yes | 11 (6.0) | |
| Histopathological Findings | Classic | 119 (64.3) |
| Folliculotropism | 28 (15.1) | |
| LCT | 9 (4.8) | |
| PPD-like | 5 (2.7) | |
| GSS | 1 (0.5) | |
| Syringotropic | 1 (0.5) | |
| Granuloma Annulare-like | 1 (0.5) | |
| Immunohistochemical Findings | CD4 (+) CD8 (−) | 153 (82.7) |
| CD4 (−) CD8 (+) | 28 (15.1) | |
| CD4 (−) CD8 (−) | 2 (1.0) | |
| CD4 (+) CD8 (+) | 2 (1.0) | |
| CD30 (+) | 4 (2.1) | |
| Initial Treatment Type | Skin-directed | 149 (80.0) |
| Systemic | 6 (3.3) | |
| Combined | 30 (16.7) | |
| Initial Treatment | Topical Corticosteroid | 6 (3.3) |
| Bexarotene Gel | 1 (0.5) | |
| nbUVB | 65 (35.1) | |
| PUVA | 77 (41.6) | |
| PUVA + Bexarotene Gel | 1 (0.5) | |
| Methotrexate (MTX) | 2 (1.0) | |
| Acitretin | 3 (1.6) | |
| Interferon (IFN) | 1 (0.5) | |
| nbUVB + Acitretin | 1 (0.5) | |
| nbUVB + IFN | 1 (0.5) | |
| PUVA + Acitretin | 2 (1.0) | |
| PUVA + IFN | 24 (12.9) | |
| PUVA + MTX | 1 (0.5) | |
| ECP + IFN | 1 (0.5) | |
| Period (Mean) | ||
| Age at Diagnosis (Years) | 50.8 | |
| Age of Onset of Lesions (Years) | 45.9 | |
| Follow-up Time (Years) | 5.6 | |
| Time from Appearance to Diagnosis (Months) | 56.3 | |
Pigmented Purpuric Dermatosis (PPD); Granulomatous Slack Skin (GSS); lactate dehydrogenase (LDH); Large Cell Transformation (LCT); Narrowband Ultraviolet B (nbUVB); Psoralen Ultraviolet A (PUVA); Methotrexate (MTX); Interferon (IFN); Extracorporeal Photopheresis (ECP).